Skip to content

Comparison of pre- and post cardiopulmonary bypass tranexamic acid effect on the amount of bleeding after coronary artery bypass graft surgery

Comparison of pre- and post cardiopulmonary bypass tranexamic acid effect on the amount of bleeding after coronary artery bypass graft surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015090723933N1
Enrollment
60
Registered
2015-09-18
Start date
2015-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amount of bleeding in Coronary Artery Bypass Graft Surgery. Other acute ischaemic heart diseases

Interventions

Intervention 1: Intervention: 20mg/kg Tranexamic acid before surgical incision. Intervention 2: Control: 20mg/kg Tranexamic acid 10 minutes after getting Cardiopulmunary bypass.
Prevention
Intervention: 20mg/kg Tranexamic acid before surgical incision
Control: 20mg/kg Tranexamic acid 10 minutes after getting Cardiopulmunary bypass

Sponsors

Tabriz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Patients under 75 years old candidate for cardiopulmunary Artery Bypass Graft surgery in the operation room of Tabriz Shahid Madani Hospital. Exclusion criterua: Emergency surgery; Coagulopathy problems like Hemophilia, platelate below 100000 per ml, PT and PTT 1.5 times above normal range; Renal failure (Serum creatinine over 2mg/dl ); Allergy to Tranexamic acid;Existence of trombotic state (Subaracnoid Hemmorage, gallBladder disease,Vein thrombosis, Emboli); Plavix ( Clopidogrel) consumption during 7 days before operation; Streptokinase consumption during 48 hours before operation; Patients with poor heart contraction power (EF<35%); Aspirin consumption with high dose during 48 hours before operation; Repeated heart surgery operation (Redo);Active liver disease; Patients with Hb<10 g/dl

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Amount of bleeding. Timepoint: During operation upto discharge. Method of measurement: Amount of bleeding from chest bottle per ml.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Sohrab Negargar

Tabriz University of Medical Sciences, Shahid Madani Hospital

mosharkesh@tbzmed.ac.irmosharkesh@gmail.comnaghipourb@tbzmed.ac.ir+98 41 3337 3919

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026